Rik Bryan
Rik Bryan is the Director of The Bladder Cancer Research Centre at the University of Birmingham and Professor in Urothelial Cancer Research. He is a former clinical urologist who became a full-time bladder cancer research academic in 2009, subsequently establishing a dedicated bladder cancer research laboratory group at the University of Birmingham. Initially focusing on urinary biomarkers and proteomics, the team expanded to incorporate genomics & bioinformatics, novel therapeutics, and bio-medical engineering, all within an ethos of translation and clinical research.
Jill Walker
Jill is an experienced Scientist (BSc, PHD) with over 20yr experience in Oncology Pharma. As the current Head of Early-Stage Disease Diagnostics, Jill has a key role in delivering the AZ strategy to intercept disease early using novel technologies as the next generation of diagnostics. Building on her experience devising and leading the AZ IO and ADC Diagnostic strategies Jill has first-hand, practical experience of working in all stage of clinical development, building innovative regulatory strategies to secure drug and diagnostic approval and establishing effective Cross-Industry collaborations to meet the needs of patients living with Cancer.
Dr Gwen Murphy
Dr Gwen Murphy earned a PhD in Clinical Medicine from Trinity College Dublin, Ireland, in 2005, and a Masters in Public Health from University College Dublin in 2006. Dr Murphy joined DCEG as an NCI Cancer Prevention Fellow within the Infections and Immunoepidemiology Branch in 2006, where she worked with Dr Charles Rabkin to initiate the NCI International EBV-Gastric Cancer Consortium. During her fellowship she also collaborated with Dr Amanda Cross on a suite of molecular epidemiology studies within the Polyp Prevention Trial. In 2009, Dr Murphy moved to the Nutritional Epidemiology Branch as a Research Fellow, becoming a Staff Scientist in 2012.
Ashley Eater
Ashley Eater is Head of Business Development and Partnerships, Global Oncology Diagnostics at AstraZeneca, where he leads a team creating partnerships with diagnostic and related companies to increase patient access to oncology medicines worldwide. He recently co-led development of AstraZeneca’s in-market strategy for early detection and screening and is excited about opportunities to improve early detection in underserved tumour types, use of multi-cancer early detection, and strengthening screening in emerging markets and through broad collaboration. Previously Ashley worked in companion diagnostic marketing, development, and in scientific consulting. He has a PhD from the University of Cambridge in Molecular Biology and sits on the board of the Precision Cancer Consortium.
Anita Grigoriadis
Anita Grigoriadis is a Reader in Cancer Bioinformatics in the School of Cancer and Pharmaceutical Sciences, the Non-Clinical Deputy Head for the Breast Cancer Now Unit, and
an executive member of the CRUK City of London Centre.
After finishing her degree at the Institute of Molecular Pathology, University of Vienna (Austria), Anita pursued a joint PhD between the Ludwig Institute for Cancer Research, London UK and Faculty of Natural Sciences, Salzburg Austria.
Anita conducted her postdoctoral training on breast cancer genomics with Professor Alan Ashworth at Breakthrough Breast Cancer Centre (London).
In 2008, she joined the Breast Cancer NOW Unit (formerly Breakthrough Breast Cancer Research) at King’s under the leadership of Professor Andrew Tutt and started her own team in 2013. Currently, Anita is a committee member of The Clinical Trial Pathology Advisory Group of the Cellular Molecular Pathology (NCRI programme), and recently the Research Subcommittee of the Pathological Society.
Rathi Srinivas
Joël Palix
James McCroskery
Angie Tebbe
Angie Tebbe is the co-founder and CEO of Rae Wellness. A fruitful 13-year career at one of the world's most recognizable retailers, a lifelong commitment to well-being, and an endless thirst for knowledge led Angie to start Rae Wellness, a holistic wellness company that is committed to well-being for all by providing natural supplements at affordable price points.
The North Dakota native grew up in a humble and holistic home. Angie's mother worked as a nurse, and her father had a deep passion for Eastern medicine. At a young age, Angie learned how to meditate and developed a curiosity for wellness. In 2018, a period of reflection sparked the idea of Rae Wellness. She gave up her title-holder role at Target, dusted off her father's books, and decided to pursue a new path.
Within a year of starting Rae, Angie launched 20 new products and orchestrated distribution in every Target location. Speaking directly to her consumer base, Angie emphasized the importance of wellness for women. Rae has reached nearly two million customers in the first two years of business, with 68% of customers falling in the 24-35 age range. Rae’s products are available at Amazon, Anthropologie, CVS Pharmacy, Target, Thrive Market, Standard Dose, Whole Foods Market, and more.
Before co-founding Rae Wellness, Angie spent over a decade at Target. As a leader in merchandising, Angie spearheaded the introduction of new brands and designer collaborations while managing P&L and personnel.
Outside of Rae Wellness, Angie loves traveling, cooking, and entertaining. Most importantly, she is a wife and mother of three children ranging in age from 7 years to 6 months.